Why GLP‑1s are reshaping employer pharmacy spend

In early 2026, a benefits manager for a 900-employee manufacturer asked a question that’s become all too familiar: “We spent $420,000 on GLP‑1 drugs last year. Do we keep covering them for weight loss?” That single therapeutic class represented 21% of total pharmacy spend, even though only 28 employees had prescriptions. It’s not an outlier. Employer plans across the country are reporting GLP‑1 utilization still up more than 25% year over year, cementing these drugs as the chief driver of PMPM increases.

Semaglutide and tirzepatide aren’t new, but by 2025 and 2026, their dual use for diabetes and obesity hit levels few projected. Monthly costs hover between $900 and $1,300, often topping $15,000 per member each year. A small group of users can throw off stop-loss modeling entirely. So now, coverage decisions for GLP‑1s sit at the uneasy intersection of finance, compliance, and morale. It’s where every benefits leader finds themselves sooner or later.

Setting coverage criteria without inviting backlash

Employers that manage this well draw a clear line between diabetes care and weight management. For Type 2 diabetes, most PBMs still treat GLP‑1s as preferred options after metformin or an SGLT‑2 inhibitor. Weight-loss use, though, is getting tougher to justify without structure. Typical 2026 plan language includes BMI thresholds (≥30, or ≥27 with a comorbidity) plus proof of participation in a lifestyle or nutrition program before approval. Even first fills are often capped at three months, with renewals tied to documented weight-loss progress, according to RxPBM.ai plan reviews.

Step therapy helps too. Requiring lower-cost therapies like liraglutide or generic phentermine-topiramate before GLP‑1s aligns coverage with actual medical need and smooths out utilization spikes. But guardrails only work when they’re clearly explained. It’s confusion that sends employees to HR, not the restriction itself. Spell out the rationale in plain language, what coverage is for, what it isn’t, and why.

Actively managing cost through PBM coordination and timing

Prior authorization alone won’t save a plan. Timing and PBM coordination now define real cost management. Employers negotiating 2026 renewals are falling into two camps. Some drop GLP‑1s for weight loss entirely, steering employees to self-pay routes through RxSaver.ai or manufacturer coupons. Others keep coverage but hand off oversight to a specialized clinical vendor that tracks adherence and reimbursement with far more precision than a general PBM model allows.

I worked with a 500-person professional services firm that ended 2025 with a $1.2M pharmacy bill, $310,000 of it from GLP‑1s. Their fix was pragmatic: a physician attestation confirming six months of nutrition or exercise counseling pre‑approval, plus a single mail‑order partner tied to NADAC-based pricing. Their PMPM fell $14 the next year, even as 10 new members started therapy. The timing, folded into PBM renewals and rebate reconciliation, made the savings stick.

Rebates deserve scrutiny too. GLP‑1 rebates can top $8,000 per script per year, but not all rebate accumulation equals lower net cost. Transparent PBMs like Capital Rx, Navitus, and RxBenefits break down gross‑to‑net results clearly. Some others, less so. Ask for real modeled data before signing. Don’t rely on glossy proposal language, it hides the math that matters.

Communicating with employees before restrictions go live

These medications feel personal for members. Changing coverage feels personal too. The smartest HR teams over‑communicate well before a new policy starts. Roughly sixty days out, strong employers circulate a manager brief and a member FAQ explaining what’s changing, why, and who to call for individual review. That small prep window changes everything.

Show the math. When employees see the plan paying $1,100 for a monthly box of pens, and how that cost rolls into next year’s premiums, conversations shift from anger to curiosity. Some employers show direct “what-if” examples: without lifestyle requirements, GLP‑1 use alone would hike premiums by 5%. Others highlight health coaching and nutrition programs alongside the policy. Look, framing the change as a health outcome initiative instead of a budget cut keeps trust intact.

What to do this quarter

For Q2 2026, start by running a claims extract of all GLP‑1 activity, including members paying with discount cards outside your PBM if possible. Share that dataset with your pharmacy benefits consultant and model a few versions: diabetes‑only, step therapy, full exclusion. Then bake your preferred strategy into upcoming PBM or carve‑out RFP documents, it’s the only way to have leverage before renewal.

Cost‑control tools exist. They work only when paired with policy direction that leadership actually stands behind. Wait until open enrollment and you lose another plan year to drift. Pull the numbers now, align your execs by midsummer, and by fall your communication plan can explain, not scramble to justify, whatever GLP‑1 coverage path you choose for 2027.